THERMO FISHER SCIENTIFIC INC.
At today's price, THERMO FISHER SCIENTIFIC INC. (TMO) is priced for +21.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Thermo Fisher is the picks-and-shovels vendor to the entire life-sciences economy, $45.2B of trailing revenue across consumables, instruments, and services, with $4.65B returned to shareholders over the past year and a fresh $9 billion acquisition of Clario extending its clinical-trial data business [Source: company press releases, Q1 2026]. • The risk is the price, not the business: today's level embeds operating-profit growth of roughly 21.6% a year for five years, a pace only about 35% of c
Is TMO overvalued? See what's priced in →
2,524 institutional managers reported holding TMO in 13F filings for the quarter ended 2026-03-31. Together they hold about 88% of the company; the top 10 hold 37%. 126 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 4.4M shares were sold short as of the 2026-06-15 count, about 1% of shares outstanding (2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TMO has cut its share count 5.3% over the past five years, spending $16.00B on repurchases. It pays a dividend, and has for 14 years running, raised 8 years straight; the current rate is $1.72 a share annually. Cash returned over the past three years: $1.65B in dividends and $10.00B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TMO over the trailing three years: 2024: 2 buys totaling $11k. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TMO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-05-07 | +6.2% | +1.3% |
| 2022-08-06 | +2.8% | -11.3% |
| 2022-11-05 | -3.2% | +8.0% |
| 2023-02-24 | +2.9% | +2.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TMO's latest 8-K filings: 2026-05-26 (items 5.07); 2026-04-23 (items 2.02, 9.01); 2026-03-24 (items 8.01, 9.01); 2026-02-12 (items 1.01, 8.01, 9.01); 2026-01-29 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.